metaOBS - - Real World Evidence KB

Treament	Trials	Summary Endpoints
Demonstrated or suggested benefit	Inconclusive results	Uncertain results	Safety results
Immunostimulants drugs	7	demonstrated 28 % decrease in clinical deterioration	inconclusive results for: death D28; death or transfer to ICU; deaths; clinical improvement; clinical improvement (14-day); hospitalization; mechanical ventilation; viral clearance ; viral clearance (time to event analysis only); viral clearance by day 14; viral clearance by day 7; ICU admission; serious adverse events; adverse events	suggested 91 % increase in clinical improvement (7-day) but the degree if certainty is unassessable suggested 34 % decrease in death or ventilation but the degree if certainty is unassessable suggested 48 % increase in hospital discharge but the degree if certainty is unassessable	-
Immunosuppressants drugs	6	suggested 32 % decrease in deaths demonstrated 47 % decrease in clinical deterioration demonstrated 21 % decrease in death or ventilation	inconclusive results for: death D28; deaths (time to event analysis only); clinical improvement; mechanical ventilation; serious adverse events	suggested 23.9-fold increase in hospital discharge but the degree if certainty is unassessable suggested 96 % decrease in ICU admission but the degree if certainty is unassessable	-
anti-inflammatory therapies	4	none	inconclusive results for: death D28; deaths; clinical deterioration; mechanical ventilation; viral clearance ; viral clearance by day 7; ICU admission; serious adverse events; adverse events	suggested 2.9-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable	-
Kinase inhibitors	1	none	-	-	-
Apilimod	0	-	-	-	-
corticosteroids	0	-	-	-	-
inhaled corticosteroids	0	-	-	-	-
leflunomide	0	-	-	-	-
meplazumab	0	-	-	-	-
pirfenidone	0	-	-	-	-
Polyinosinic-Polycytidylic Acid	0	-	-	-	-
sargramostim	0	-	-	-	-
statins	0	-	-	-	-
thymosin	0	-	-	-	-

Treament

Trials

Summary Endpoints

Demonstrated or suggested benefit

Inconclusive results

Uncertain results

Safety results

Immunostimulants drugs

7

demonstrated 28 % decrease in clinical deterioration

inconclusive results for: death D28; death or transfer to ICU; deaths; clinical improvement; clinical improvement (14-day); hospitalization; mechanical ventilation; viral clearance ; viral clearance (time to event analysis only); viral clearance by day 14; viral clearance by day 7; ICU admission; serious adverse events; adverse events

suggested 91 % increase in clinical improvement (7-day) but the degree if certainty is unassessable

suggested 34 % decrease in death or ventilation but the degree if certainty is unassessable

suggested 48 % increase in hospital discharge but the degree if certainty is unassessable

-

Immunosuppressants drugs

6

suggested 32 % decrease in deaths

demonstrated 47 % decrease in clinical deterioration

demonstrated 21 % decrease in death or ventilation

inconclusive results for: death D28; deaths (time to event analysis only); clinical improvement; mechanical ventilation; serious adverse events

suggested 23.9-fold increase in hospital discharge but the degree if certainty is unassessable

suggested 96 % decrease in ICU admission but the degree if certainty is unassessable

-

anti-inflammatory therapies

4

none

inconclusive results for: death D28; deaths; clinical deterioration; mechanical ventilation; viral clearance ; viral clearance by day 7; ICU admission; serious adverse events; adverse events

suggested 2.9-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable

-

Kinase inhibitors

1

none

-

Apilimod

0

-

corticosteroids

0

-